Millions Share a Deadly Genetic Heart Risk. This Experimental Drug Could Be a Game Changer
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Drug reduces mysterious particle involved in heart attack risk
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
BioPharma Dive9h
Lilly study data reinforce potential of new kind of heart drug
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
Nurse-led heart health counseling reduces serious cardiac events after acute coronary syndrome
Patients who were counseled on heart medications and lifestyle modifications by specially trained nurses were 30% less likely ...
Endpoints News9h
Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...